Received: 21/12/2016; Revised: 21/03/2017; Accepted: 11/05/2017 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/eji.201646903. This article is protected by copyright. All rights reserved. Exploiting scavenger receptors in cancer immunotherapy: Lessons from CD5 and SR-B1 Marcos Vasquez 1* , Inês Simões 2* , Marta Consuegra-Fernández 2 , Fernando Aranda 2 , Francisco Lozano 2,3,4† and Pedro Berraondo 1† 1 Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain; Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Navarra Institute for Health Research (IdiSNA), Pamplona, Navarra, Spain; 2 Institut d’Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; 3 Department of Immunology, Hospital Clínic of Barcelona, Barcelona, Spain; 4 Departament de Biomedical Sciences, University of Barcelona, Barcelona, Spain. † Correspondence to: Pedro Berraondo (pberraondol@unav.es) Francisco Lozano (flozano@clinic.ub.es)